AIM · AIM ImmunoTech Inc. Common Stock
View on chartInsiders & Stakes
| Ted D. Kellner Director | ▲ Buy | Open Market | 1,969,504 Shares held | 4/11/2025 | View profile |
| William M. Mitchell Director | ▲ Buy | Open Market | 521,723 Shares held | 4/11/2025 | View profile |
| Peter W. Rodino III COO, Secretary, Gen. Counsel | ▲ Buy | Open Market | 401,762 Shares held | 4/4/2025 | View profile |
| Stewart Appelrouth Director | ▲ Buy | Grant | 388,729 Shares held | 12/31/2024 | View profile |
| Nancy Bryan Director | ▲ Buy | Grant | 291,882 Shares held | 3/14/2025 | View profile |
| Thomas K. Equels CEO & President | ▲ Buy | Open Market | 126,822 Shares held | 9/17/2026 | View profile |
| David I. Chemerow Director | ▼ Sell | Other | 28,441 Shares held | 3/12/2026 | View profile |
Transaction History
| Thomas K. Equels | ▲ Buy | Open Market | 24,000 | $5K | 9/17/2026 |
| Thomas K. Equels | ▲ Buy | Open Market | 11,000 | $2K | 9/16/2026 |
| Thomas K. Equels | ▲ Buy | Open Market | 22,000 | $5K | 9/15/2026 |
| Thomas K. Equels | ▲ Buy | Open Market | 5,900 | $1K | 9/14/2026 |
| Thomas K. Equels | ▼ Sell | Other | 25,000 | $0 | 3/12/2026 |
| David I. Chemerow | ▼ Sell | Other | 25,000 | $0 | 3/12/2026 |
| David I. Chemerow | ▲ Buy | Grant | 2,800 | $3K | 2/5/2026 |
| Thomas K. Equels | ▲ Buy | Open Market | 107 | $824 | 6/13/2025 |
| Thomas K. Equels | ▲ Buy | Open Market | 103 | $896 | 6/12/2025 |
| William M. Mitchell | ▲ Buy | Open Market | 196,851 | $5K | 4/11/2025 |
| Thomas K. Equels | ▲ Buy | Open Market | 1,968,504 | $50K | 4/11/2025 |
| Ted D. Kellner | ▲ Buy | Open Market | 1,968,504 | $50K | 4/11/2025 |
| Thomas K. Equels | ▲ Buy | Open Market | 41,000 | $3K | 4/4/2025 |
| Peter W. Rodino III | ▲ Buy | Open Market | 500 | $44 | 4/4/2025 |
| William M. Mitchell | ▲ Buy | Grant | 44,899 | $5K | 3/14/2025 |
| Nancy Bryan | ▲ Buy | Grant | 44,899 | $5K | 3/14/2025 |
| David I. Chemerow | ▲ Buy | Grant | 44,899 | $5K | 3/14/2025 |
| Thomas K. Equels | ▲ Buy | Open Market | 50,000 | $7K | 3/5/2025 |
| Thomas K. Equels | ▲ Buy | Open Market | 44,000 | $5K | 3/4/2025 |
| Thomas K. Equels | ▲ Buy | Open Market | 83,334 | $10K | 3/4/2025 |
| David I. Chemerow | ▲ Buy | Grant | 19,290 | $3K | 2/28/2025 |
| William M. Mitchell | ▲ Buy | Grant | 38,580 | $5K | 2/28/2025 |
| Nancy Bryan | ▲ Buy | Grant | 38,580 | $5K | 2/28/2025 |
| William M. Mitchell | ▲ Buy | Grant | 43,330 | $5K | 2/14/2025 |
| Nancy Bryan | ▲ Buy | Grant | 43,330 | $5K | 2/14/2025 |
| William M. Mitchell | ▲ Buy | Grant | 25,797 | $5K | 1/31/2025 |
| Nancy Bryan | ▲ Buy | Grant | 25,797 | $5K | 1/31/2025 |
| Nancy Bryan | ▲ Buy | Grant | 27,412 | $5K | 1/15/2025 |
| William M. Mitchell | ▲ Buy | Grant | 27,412 | $5K | 1/15/2025 |
| Stewart Appelrouth | ▲ Buy | Grant | 8,768 | $2K | 12/31/2024 |
| Nancy Bryan | ▲ Buy | Grant | 26,305 | $5K | 12/31/2024 |
| William M. Mitchell | ▲ Buy | Grant | 26,305 | $5K | 12/31/2024 |
| William M. Mitchell | ▼ Sell | Open Market | 4,580 | $884 | 12/19/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 22,727 | $5K | 12/18/2024 |
| William M. Mitchell | ▲ Buy | Grant | 24,452 | $5K | 12/13/2024 |
| Stewart Appelrouth | ▲ Buy | Grant | 24,452 | $5K | 12/13/2024 |
| Nancy Bryan | ▲ Buy | Grant | 24,452 | $5K | 12/13/2024 |
| Stewart Appelrouth | ▲ Buy | Open Market | 1 | $0 | 12/2/2024 |
| Stewart Appelrouth | ▲ Buy | Open Market | 11,111 | $2K | 12/2/2024 |
| William M. Mitchell | ▲ Buy | Grant | 22,645 | $5K | 12/2/2024 |
| Stewart Appelrouth | ▲ Buy | Grant | 22,645 | $5K | 12/2/2024 |
| Nancy Bryan | ▲ Buy | Grant | 22,645 | $5K | 12/2/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 20,000 | $4K | 11/21/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 85,000 | $17K | 11/20/2024 |
| Stewart Appelrouth | ▲ Buy | Open Market | 81,953 | $16K | 11/20/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 60,110 | $11K | 11/20/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 5,000 | $2K | 9/16/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 20,000 | $6K | 9/13/2024 |
| Thomas K. Equels | ▲ Buy | Grant | 312,500 | $100K | 9/11/2024 |
| Thomas K. Equels | ▲ Buy | Grant | 377,358 | $100K | 8/12/2024 |
| Peter W. Rodino III | ▲ Buy | Grant | 188,679 | $50K | 8/12/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 61,729 | $25K | 5/6/2024 |
| Peter W. Rodino III | ▲ Buy | Open Market | 30,865 | $13K | 5/6/2024 |
| Nancy Bryan | ▲ Buy | Open Market | 38,462 | $15K | 3/21/2024 |
| Stewart Appelrouth | ▲ Buy | Open Market | 90,910 | $30K | 3/15/2024 |
| Peter W. Rodino III | ▲ Buy | Open Market | 37,879 | $13K | 3/15/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 75,758 | $25K | 3/15/2024 |
| Thomas K. Equels | ▲ Buy | Open Market | 33,861 | $15K | 11/27/2023 |
| Thomas K. Equels | ▲ Buy | Open Market | 22,676 | $10K | 9/29/2023 |
| Thomas K. Equels | ▲ Buy | Open Market | 8,222 | $6K | 8/25/2023 |
| Thomas K. Equels | ▲ Buy | Open Market | 14,993 | $10K | 8/24/2023 |
| Thomas K. Equels | ▲ Buy | Open Market | 16,950 | $10K | 7/17/2023 |
| Stewart Appelrouth | ▼ Sell | Other | 68,208 | $84K | 3/10/2023 |
| Peter W. Rodino III | ▲ Buy | Open Market | 80,646 | $25K | 1/3/2023 |
| Thomas K. Equels | ▲ Buy | Open Market | 161,291 | $50K | 1/3/2023 |
| Stewart Appelrouth | ▲ Buy | Open Market | 80,646 | $25K | 1/3/2023 |
| Thomas K. Equels | ▲ Buy | Grant | 32,895 | $25K | 7/18/2022 |
| Peter W. Rodino III | ▲ Buy | Grant | 4,902 | $5K | 4/25/2022 |
| Thomas K. Equels | ▲ Buy | Grant | 49,020 | $50K | 4/25/2022 |
| Stewart Appelrouth | ▲ Buy | Grant | 24,500 | $26K | 4/25/2022 |
| Thomas K. Equels | ▲ Buy | Grant | 21,552 | $25K | 12/13/2021 |
| Thomas K. Equels | ▲ Buy | Grant | 11,811 | $15K | 12/10/2021 |
| Stewart Appelrouth | ▲ Buy | Grant | 19,379 | $25K | 11/24/2021 |
| Thomas K. Equels | ▲ Buy | Grant | 11,627 | $15K | 11/24/2021 |
| Thomas K. Equels | ▲ Buy | Grant | 11,194 | $15K | 11/23/2021 |
| Thomas K. Equels | ▲ Buy | Grant | 10,204 | $15K | 11/19/2021 |
| Thomas K. Equels | ▲ Buy | Grant | 9,146 | $15K | 11/17/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress
AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress. AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.